Skip to content
Screener

Shattuck Labs, Inc. STTK Stock-Based Comp

Stock-Based Comp at other companies

Eli Lilly logo
Eli LillyLLY
$201M+8.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$458M+11.7%
Amgen logo
AmgenAMGN
$165M+5.1%
AbbVie logo
AbbVieABBV
$444M+8.3%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$2.67M-12.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$5.31M+95.2%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$681.93M+1,826%
Enterprise value$621.3M-5,241%
P/S681.9×+670×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash flows used in operating activities:
Net loss$(29,919)$(26,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation5,1483,611
Depreciation1,7421,865
Non-cash operating lease expense(417)241
Net accretion of investments(243)(1)
Changes in operating assets and liabilities:

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s stock-based comp?
Shattuck Labs, Inc. (STTK) reported stock-based comp of $2.73M in Q2 2026.
How has Shattuck Labs, Inc.'s stock-based comp changed year-over-year?
Shattuck Labs, Inc.'s stock-based comp increased by 44.6% year-over-year, from $1.89M to $2.73M.
What is the long-term trend for Shattuck Labs, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s stock-based comp has grown at a 6.4% compound annual growth rate (CAGR), from $5.47M to $7M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Shattuck Labs, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude